ISRCTN13447477进行中（未招募）未知
A pilot study of virucidal activity of povidone-iodine (PVP-I) 0.5% aqueous solution oral/nasal spray and mouthwash in people with COVID-19 and confirmed oral/nasal shedding of SARS-CoV-2
Royal Surrey County Hospital NHS Foundation Trust0 个研究点目标入组 22 人开始时间: 2020年5月22日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Adults aged =18 years and =75 years
- •2. Have confirmed COVID-19 symptoms and symptom onset within the past 10 days
- •3. Recently (within last 3-4 days) hospitalised with COVID-19 disease
- •4. COVID-19 disease proven by PCR testing for SARS-CoV-2 within the last 4 days
- •5. Capable of using a nasal spray device and the mouthwash required by the trial
- •6. Capacity and capability to give informed consent to take part in the trial
排除标准
- •1. Known sensitivity to PVP-I aqueous antiseptic solution or any of its listed excipients
- •2. Previously diagnosed thyroid disease
- •3. Chronic renal failure (stage =3 by eGFR MDRD)
- •4. Acute renal failure (KDIGO =stage 2: creatinine =2x baseline)
- •5. Known pregnancy or currently breastfeeding
- •6. Current requirement for invasive or non-invasive ventilation or planned within next 6 hours
- •7. Patient undergoing or soon to undergo radioiodine treatment
- •8. Known dermatitis herpetiformis (Duhring's disease)
- •9. Current participation in research that is designed to, or is expected to alter the COVID-19 disease course or viral load.
- •10. Inability to communicate in English or read English
研究者
相似试验
已完成
1 期
Virucidal pilot study of Nasodine® (povidone-iodine 0.5%) nasal spray in people in South Africa with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.COVID-19 PositiveInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12621000034831Firebrick Pharma Limited23
已完成
不适用
In vivo evaluation of the virucidal efficacy of Chlorhexidine and Povidone-iodine mouthwashes against salivary SARS-CoV-2COVID-19/Transmission during dental treatments.Antiseptic oral mouthrinsePreventionC06.9LBCTR2021034768ebanese University77
进行中（未招募）
不适用
Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive patients for 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II)EUCTR2008-003538-11-CZBoehringer Ingelheim RCV GmbH & Co. KG700
进行中（未招募）
不适用
Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive patients for 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II)Proposed new title:Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve and treatment-experienced patients for 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (double blinded, randomised, placebo controlled, Phase II)EUCTR2008-003538-11-PTBoehringer Ingelheim Pharma GmbH & Co. KG700
进行中（未招募）
1 期
Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II).EUCTR2008-003538-11-FRBoehringer-Ingelheim France420